The guidelines of the European Association of Urology recommend ICI combination therapy as the first-line treatment for mRCC [9]. There is no established drug selection for the second-line treatment of mRCC, but several studies suggest that second-line treatment consists of nivolumab monotherapy or TKI [9]. On the other hand, the effectiveness of TKI and ICI greatly depends on the tumor microenvironment, but it varies in RCC due to several patient factors including tumor heterogeneity [10]. For RCC, the characteristics of metastatic tumor cells and the surrounding microenvironment may not always match those of primary tumors [11]. Therefore, a comparative analysis of the molecular biomarker expression profiles of primary and metastatic specimens, such as bone, should be performed [12].
The bone matrix is inherently rich in growth factors, making it a favorable and fertile environment for metastatic tumors, irrespective of the primary tumor type. BM is considered a poor prognostic factor for patients with mRCC [13]. In the microenvironment of BM lesions, regulatory T-cells and myeloid-derived suppressor cells are abundant, which suppresses tumor immunity [14, 15], which may lead to poor prognosis for mRCC patients with BM. Moreover, in RCC, inactivation of the von Hippel-Lindau tumor suppressor gene is common and leads to an increase in hypoxia-inducible factor-alpha, resulting in the overexpression of vascular endothelial growth factor (VEGF) [16]. This growth factor promotes tumor angiogenesis and plays a crucial role in the invasion and metastasis of RCC. On the other hand, tyrosine kinase is an important enzyme in intracellular signal transduction, and binding of VEGF to the VEGF receptor (VEGFR) increases receptor tyrosine kinase activity and initiates intracellular signal transduction. Considering above, we aimed to compare the efficacies of nivolumab and TKIs as second-line treatments for patients with mRCC with BM, elucidating the differences between the tumor microenvironments of primary and BM lesions.
In this study, we present two novel findings. First, we found that TKIs were more effective as second-line treatments for BM lesions in RCC than nivolumab monotherapy, as evidenced by the higher ORR at the BM sites (Table 3). Previous studies have shown a significant difference in the treatment efficacy of ICI across metastatic lesions [17]. In a large-scale tumor-agnostic study, BM lesions were associated with resistance to ICI [18]. In patients with mRCC treated with second-line nivolumab, treatment efficacy varies significantly with the metastatic site [19], with bone exhibiting a particularly low ORR of 5%, compared to 36% for lung and 50% for liver metastases [7]. In patients with mRCC treated with nivolumab as second-line therapy or beyond, BM, rather than lung or lymph node metastases, was associated with poor progression-free survival (PFS) and OS [20]. In the present study, an elevated serum ALP concentration, which reflects the overall deterioration of systemic conditions such as BM volume, was an independent poor prognostic factor for second-line treatment of mRCC with BM (Table 2). Considering above, TKIs are considered a promising option for patients with mRCC with BM and without other visceral metastases.
Second, VEGFR2 expression was higher in BM lesions than in primary tumors, and BM lesions showed a trend of decreased CD8+ tumor-infiltrating T-lymphocytes and tumor-infiltrating CD20+ B-cells (Fig. 5), which may contribute to the lower ORR of nivolumab than of TKI for BM lesions. Tao et al. reported that tumor-infiltrating B-lymphocytes in mRCC have been shown to recruit and activate CD8+ tumor-infiltrating T-lymphocytes, thereby enhancing anti-tumor effects [21], and this process is involved in the formation of tertiary lymphoid structures [22]. TKIs are also considered more likely to be effective for cases of RCC with high expression of VEGFR2 [23]. In this study, we described a significant increase of VEGFR2- positive cells in BM sites, demonstrating the potential benefits of TKI in patients with mRCC with BM. Especially, considering that cabozantinib displayed the strongest inhibition toward VEGFR2 among several types of TKIs, cabozantinib may likely contributes to the enhanced antitumor activity in BM [24].
This study had several limitations. First, this was a retrospective study with a few cases. While it was a multicenter study including five hospitals, the number of patients with mRCC with BM receiving second-line treatment was limited, and even fewer underwent surgery for BM lesions. Therefore, future studies with larger sample sizes and more extensive designs are warranted. Second, we used the MDA criteria and Response Evaluation Criteria in Solid Tumors to evaluate the treatment efficacy for BM lesions, but there is currently no consensus on the best response evaluation system for them [25]. Notwithstanding, several studies have used the MDA criteria to evaluate BM lesions [26].
In this study, we revealed that TKIs may have higher efficacy than nivolumab against BM lesion and poor IMDC risk classification and elevated serum ALP concentrations are associated with worse prognosis in patients with mRCC and BM receiving second-line therapy. In patients with mRCC with metastases limited to the bone, TKIs may be more effective than nivolumab.